Learn about the challenges associated with the management of transformed indolent lymphomas and the recent advances in management to help you to incorporate novel therapies into routine clinical practice in the appropriate patient population to improve clinical outcomes.

Learn about the recent advances as well as the challenges involved in the diagnosis and management of classical hairy cell leukemia (HCL) and HCL-variant.

This topic will help fill the gap between current and ideal practice by reviewing examples and best practice recommendations that pharmacists can implement in collaboration with interprofessional team members to improve resource utilization, patient safety, and quality of care.

The flurry of changes to the PARPi indications can cause considerable confusion in clinical practice. It may be difficult for health care professionals to keep track of the emerging data and understand how to apply it to patient care. It is important that health care professionals, including pharmacists, are able to educate their patients on the risks vs. benefits of these agents to help empower them to make informed decisions regarding their treatment.

Learn about the results of recent trials, updates to NCCN Guideline recommendations, and common supportive care needs, so that you can provide optimal management for patients with metastatic prostate cancer.

Advances in pharmacogenomics are widespread in the treatment of cancer. The ongoing research in pharmacogenomics has played a vital role in the diagnosis and treatment of oncologic disease states. It is imperative for the interprofessional oncology care team to have a strong understanding of pharmacogenomics and the ability to correctly apply the standard of care for their patients.

This program will provide expert insights on the current recommendations of care for patients with breast cancer and include the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

With expanding treatment options, clinicians should understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. It is important for clinicians to stay up-to-date with the available treatment options to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profiles is important to optimize patient outcomes.

Health care providers need to know about the recent updates to the NCCN Guidelines for Non-Small Cell Lung Cancer to provide the best care for their patients with NSCLC, including adverse reactions that may occur with use of the new neoadjuvant and adjuvant systemic therapy regimens.